Acesis BioMed is a biomedical company with bases in Colorado, US, and London, UK. They specialize in developing a platform of oral drug candidates for metabolic and endocrine disorders. Initially, their focus is on treating male hypogonadism (low T).

Acesis BioMed operates through Acesis Holdings Corporation and its subsidiaries, Acesis Biomed US, Inc., and Acesis Biomed Ltd. One of the key advantages of Acesis BioMed's approach is their proprietary first-in-class T peptide modulator. This modulator offers a safer solution compared to existing Testosterone Replacement Therapy (TRT).

The hypogonadism indication targets a market estimated to be worth $3 billion to $4 billion. Furthermore, there are additional market opportunities in addressing co-morbidities of low T, such as obesity, fatty liver disease, prediabetes, and cachexia. Acesis BioMed's core asset is the intellectual property developed by Dr.

Vassilios Papadopoulos and his research team. Dr. Papadopoulos has received over $12 million in research funding to support the groundwork leading to the understanding of steroidogenesis and the identification of a novel therapeutic target for T restoration.

Acesis BioMed aims to become the global standard of care for male hypogonadism treatment upon regulatory approval. (Corrected spelling error: malehypogonadism -> male hypogonadism)